U.S. Section 232 Pharmaceutical Tariffs Implemented July 31, 2026
Drug Delivery System Development →Implementation began on July 31, 2026, for new U.S. Section 232 trade tariffs targeting foreign-manufactured patented pharmaceuticals, drug combination devices, and related active ingredients. Importers face default duty rates of up to 100%, with reduced rates applying to specific partner nations (e.g., 10% for the UK and 15% for the EU and Japan) or qualified onshoring commitments (20%). Generic drugs and non-patented components remain exempt, but supply chains for proprietary delivery devices face immediate landed cost increases.
Audit foreign supply chains and evaluate domestic assembly options
Mapping product exposure against Section 232 annexes enables procurement teams to identify high-duty components and explore US-based manufacturing or tariff-exempt partners to mitigate margin compression.